Conjugates for treating diseases caused by psma expressing cells

Abstract

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

What is claimed is: 
     
         1 .- 29 . (canceled) 
     
     
         30 . A conjugate of the formula
   B-L-(D) n      or a salt thereof, wherein
 B is of the formula 
   
       
         
           
           
               
               
           
         
         
           L is a polyvalent linker comprising carbonylalkylcarbonyl; 
           D comprises a radioactive isotope of a metal coordinated to a chelating group; and 
           n is 1. 
         
       
     
     
         31 . The conjugate of  claim 30  wherein L forms an amide with the lysine. 
     
     
         32 . The conjugate of  claim 30  wherein L comprises a chain of at least about 7 atoms. 
     
     
         33 . The conjugate of  claim 30  wherein L comprises a chain of at least about 8 atoms. 
     
     
         34 . The conjugate of  claim 30  wherein L comprises a chain of at least about 9 atoms. 
     
     
         35 . The conjugate of  claim 30  wherein L comprises a chain of at least about 10 atoms. 
     
     
         36 . The conjugate of  claim 30  wherein L comprises a chain of at least about 11 atoms. 
     
     
         37 . The conjugate of  claim 30  wherein L comprises a chain of at least about 12 atoms. 
     
     
         38 . The conjugate of  claim 30  wherein L comprises a chain of at least about 13 atoms. 
     
     
         39 . The conjugate of  claim 30  wherein L comprises a chain of at least about 14 atoms. 
     
     
         40 . The conjugate of  claim 30  wherein L comprises a chain of at least about 15 atoms. 
     
     
         41 . The conjugate of  claim 30  wherein L comprises a chain of 14 atoms or 15 atoms. 
     
     
         42 . The conjugate of  claim 30  wherein L comprises a chain of 14 atoms. 
     
     
         43 . The conjugate of  claim 30  wherein L comprises a chain of 15 atoms. 
     
     
         44 . The conjugate of  claim 30  wherein L comprises a chain of between about 7 and about 26 atoms. 
     
     
         45 . The conjugate of  claim 30  wherein L comprises a chain of atoms selected from the group consisting of C, N, O, and S, and combinations thereof. 
     
     
         46 . The conjugate of  claim 30  wherein L further comprises an amino acid or an amino acid derivative. 
     
     
         47 . The conjugate of  claim 46  wherein the amino acid or amino acid derivative is selected from the group consisting of asparagine, aspartic acid, cysteine, glutamic acid, lysine, glutamine, arginine, serine, ornithine, and threonine, and derivatives of the foregoing. 
     
     
         48 . The conjugate of  claim 47  wherein the amino acid derivative is selected from the group consisting of ethers and esters of hydroxy groups; amides, carbamates, and ureas of amino groups; and esters, amides, and cyano derivatives of carboxylic acid groups. 
     
     
         49 . The conjugate of  claim 48  wherein L comprises a chain of 14 atoms or 15 atoms. 
     
     
         50 . The conjugate of  claim 48  wherein L comprises a chain of 14 atoms. 
     
     
         51 . The conjugate of  claim 48  wherein L comprises a chain of 15 atoms. 
     
     
         52 . A pharmaceutical composition comprising the conjugate of  claim 30 , and optionally one or more carriers, diluents, or excipients, or a combination thereof.